id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC11085288
core_pubmed_pmc
Pharmacological Activities of Lonicerae japonicae flos and Its Derivative—“Chrysoeriol” in Skin Diseases
Pharmacological Activities of Lonicerae japonicae flos and Its Derivative—“Chrysoeriol” in Skin Diseases Abstract Abstract Chrysoeriol is an active ingredient derived from the Chinese medicinal herb (CMH) “ Lonicerae japonicae flos ” in the dried flower bud or bloomed flower of Lonicera japonica Thunberg. Dermatoses ar...
PMC6768915
core_pubmed_pmc
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update Abstract Abstract It has been estimated by the World Health Organization (WHO) that over 71 million people were infected with the hepatitis C virus (HCV) in 2015. Since then, a number of highly effective direct-acting antiviral...
PMC7478165
core_pubmed_pmc
Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia † †Electronic supplementary information (ESI) available: General experimental details, aspects relating to cultivation of feverfew , the PTL extraction protocol, synthesis, biological assays computational information and spectrums ar...
Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia † †Electronic supplementary information (ESI) available: General experimental details, aspects relating to cultivation of feverfew , the PTL extraction protocol, synthesis, biological assays computational information and spectrums ar...
PMC5481914
core_pubmed_pmc
Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens
Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens Abstract Abstract Background The most widely used measure of potency of antimicrobial drugs is Minimum Inhibitory Concentration (MIC). MIC is usually determined under standardised conditions in broths formulated to optimise b...
PMC10088081
core_pubmed_pmc
Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder
Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder Abstract Abstract Apixaban is an oral small‐molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for...
PMC10785250
core_pubmed_pmc
Ginsenoside Rc: A potential intervention agent for metabolic syndrome
Ginsenoside Rc: A potential intervention agent for metabolic syndrome Abstract Abstract Ginsenoside Rc, a dammarane-type tetracyclic triterpenoid saponin primarily derived from Panax ginseng , has garnered significant attention due to its diverse pharmacological properties. This review outlined the sources, putative bi...
PMC8962049
core_pubmed_pmc
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers Abstract Abstract Background The tyrosine kinase receptor encoded by the MET oncogene is a major player in cancer. When MET is responsible for the onset and progression of the transformed phenotype (MET-addicted ...
PMC12973930
core_pubmed_pmc
Clinical benefits and risks of high-dose intravenous vitamin C: a systematic review
Clinical benefits and risks of high-dose intravenous vitamin C: a systematic review Abstract Abstract High-dose intravenous vitamin C (IVC) achieves plasma concentrations that are not attainable by oral administration and has been investigated as an adjunct in sepsis, oncology, and symptom management. To synthesize the...
PMC5464336
core_pubmed_pmc
Physiologically based pharmacokinetic modeling of tea catechin mixture in rats and humans
Physiologically based pharmacokinetic modeling of tea catechin mixture in rats and humans Abstract Abstract Although green tea ( Camellia sinensis) ( GT ) contains a large number of polyphenolic compounds with anti‐oxidative and anti‐proliferative activities, little is known of the pharmacokinetics and tissue dose of t...
PMC12849618
core_pubmed_pmc
Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy
Advanced nanotechnology in enhancing immune checkpoint inhibitors (ICIs) for head and neck cancer therapy Abstract The sixth most prevalent malignancy in the world, head and neck cancer (HNC), is associated with high mortality rate. Several risk factors, such as Helicobacter pylori and human papillomavirus (HPV) infect...
PMC7793822
core_pubmed_pmc
Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach
Predicting the Effects of CYP2C19 and Carboxylesterases on Vicagrel, a Novel P2Y12 Antagonist, by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Approach Abstract Vicagrel, a novel acetate derivative of clopidogrel, exhibits a favorable safety profile and excellent antiplatelet activity. Studies aim at ...
PMC9919763
core_pubmed_pmc
Establishment of LC-MS/MS Method for Determination of GMDTC in Rat Plasma and Its Application in Preclinical Pharmacokinetics
Establishment of LC-MS/MS Method for Determination of GMDTC in Rat Plasma and Its Application in Preclinical Pharmacokinetics Abstract Abstract Sodium (S)-2-(dithiocarboxylato((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)-4(methylthio)butanoate (GMDTC) is the first compound to use cadmium repellent as an indication....
PMC11396748
core_pubmed_pmc
Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition
Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition Abstract Drug resistance remains a critical barrier in cancer therapy, diminishing the effectiveness of chemotherapeutic, targeted, and immunotherapeutic agents. Overexpression of proteins such as B-cell lymphoma 2 (Bcl-2), inhibi...
PMC4467252
core_pubmed_pmc
Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects
Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects Abstract Objective Icosapent ethyl (IPE) is a prescription form of eicosapentaenoic acid (EPA) ethyl ester. This randomized, open-label study characterized EPA pharmacokinetics. Me...
PMC12592258
core_pubmed_pmc
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity
Optimizing lazertinib therapy through GSTM1 genotyping: a strategy to reduce excess drug exposure and potential toxicity Abstract Abstract Purpose The combination of lazertinib and amivantamab has shown superior efficacy over first line osimertinib in EGFR-mutated metastatic non-small cell lung cancer, but is associate...
PMC12381626
core_pubmed_pmc
Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients
Population pharmacokinetics and optimized dosing of cefuroxime in critically ill patients Abstract Abstract Cefuroxime is a second‐generation cephalosporin widely used in the intensive care unit (ICU). ICU patients have high variability in interpatient pharmacokinetics (PK), but the extent of this variation is unclear....
PMC12959153
core_pubmed_pmc
Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development
Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development Abstract ABSTRACT Use of mouse infection models for antimicrobial pharmacokinetic/pharmacodynamic (PK/PD) analysis can assist in dosing regimen design and susceptibility breakpoint development. A major hurdle for c...
PMC8565817
core_pubmed_pmc
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer Abstract ABSTRACT Bemarituzumab (FPA144) is a first-in-class, humanized, afucosylated immunoglobulin G1 monoclonal antibody (mAb) directed against fibroblast growth factor receptor 2b (FGFR2b) with two mechanisms of actio...
PMC8072337
core_pubmed_pmc
Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients
Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients Abstract Background: With the increasing use of mycophenolic acid (MPA) formulations in organ transplantation, the need for personalized immunosuppressive therapy has become well recognized based on thera...
PMC12091750
core_pubmed_pmc
Sulfamethoxazole-trimethoprim plus rifampicin combination therapy for methicillin-resistant Staphylococcus aureus infection: An in vitro study
Sulfamethoxazole-trimethoprim plus rifampicin combination therapy for methicillin-resistant Staphylococcus aureus infection: An in vitro study Abstract Methicillin-resistant Staphylococcus aureus (MRSA) is highly drug-resistant. The current Japanese guidelines (2019 edition) for managing and treating MRSA infections me...
PMC12561440
core_pubmed_pmc
Cerebrospinal Pharmacokinetic Modeling and Pharmacodynamic Simulation of High-Dose Cefazolin for Meningitis Caused by Methicillin-Susceptible Staphylococcus aureus
Cerebrospinal Pharmacokinetic Modeling and Pharmacodynamic Simulation of High-Dose Cefazolin for Meningitis Caused by Methicillin-Susceptible Staphylococcus aureus Abstract Abstract Background: Cefazolin is being increasingly used to treat central nervous system infections caused by methicillin-susceptible Staphylococc...
PMC2800315
core_pubmed_pmc
Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors Abstract Objective To determine the pharmacokinetics and safety of RAD001 (everolimus) in Japanese patients with advanced solid tumors. Methods An open-label, non-randomized, dose-escalat...
PMC6272045
core_pubmed_pmc
Interaction Between Different Extracts of Hypericum perforatum L. from Serbia and Pentobarbital, Diazepam and Paracetamol
Interaction Between Different Extracts of Hypericum perforatum L. from Serbia and Pentobarbital, Diazepam and Paracetamol Abstract Herb-drug interactions are an important safety concern and this study was conducted regarding the interaction between the natural top-selling antidepressant remedy Hypericum perforatum (Hyp...
PMC6796793
core_pubmed_pmc
Variation in Actionable Pharmacogenetic Markers in Natives and Mestizos From Mexico
Variation in Actionable Pharmacogenetic Markers in Natives and Mestizos From Mexico Abstract Abstract The identification and characterization of pharmacogenetic variants in Latin American populations is still an ongoing endeavor. Here, we investigated SNVs on genes listed by the Pharmacogenomics Knowledge Base in 1284 ...
PMC7022479
core_pubmed_pmc
In Vitro Dissolution and in Silico Modeling Shortcuts in Bioequivalence Testing
In Vitro Dissolution and in Silico Modeling Shortcuts in Bioequivalence Testing Abstract Abstract Purpose: To review in vitro testing and simulation platforms that are in current use to predict in vivo performances of generic products as well as other situations to provide evidence for biowaiver and support drug formul...
PMC7926495
core_pubmed_pmc
Preclinical Pharmacokinetics and Biodistribution of Anticancer Dinuclear Palladium(II)-Spermine Complex (Pd 2 Spm) in Mice
Preclinical Pharmacokinetics and Biodistribution of Anticancer Dinuclear Palladium(II)-Spermine Complex (Pd 2 Spm) in Mice Abstract Palladium-based compounds are regarded as potential analogs to platinum anticancer drugs with improved properties. The present study assessed the pharmacokinetics and biodistribution of a ...
PMC4840854
core_pubmed_pmc
The median effective concentration (EC50) of propofol with different doses of fentanyl during colonoscopy in elderly patients
The median effective concentration (EC50) of propofol with different doses of fentanyl during colonoscopy in elderly patients Abstract Background Propofol and fentanyl are the most widely administered anesthesia maintaining drugs during colonoscopy. In this study, we determined the median effective concentration (EC50)...
PMC10879352
core_pubmed_pmc
An In Silico Platform to Predict Cardiotoxicity Risk of Anti-tumor Drug Combination with hiPSC-CMs Based In Vitro Study
An In Silico Platform to Predict Cardiotoxicity Risk of Anti-tumor Drug Combination with hiPSC-CMs Based In Vitro Study Abstract Objective Antineoplastic agent-induced systolic dysfunction is a major reason for interruption of anticancer treatment. Although targeted anticancer agents infrequently cause systolic dysfunc...
PMC7460420
core_pubmed_pmc
Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration
Pharmacokinetics of Tildipirosin in Ewes after Intravenous, Intramuscular and Subcutaneous Administration Abstract Simple Summary Pneumonia is a significant cause of death in sheep flocks. Thus, antibiotics are essential for the treatment of bacterial pneumonia to reduce morbidity and mortality, but few drugs are speci...
PMC10432719
core_pubmed_pmc
A phase 1 study of dimdazenil to evaluate the pharmacokinetics, food effect and safety in Chinese healthy subjects
A phase 1 study of dimdazenil to evaluate the pharmacokinetics, food effect and safety in Chinese healthy subjects Abstract Abstract Background and objective: As a partial positive allosteric modulator of the gamma-aminobutyric acid A (GABAA) receptor, dimdazenil was used for the treatment of insomnia with the potentia...
PMC7150881
core_pubmed_pmc
RETRACTED: Quantification and Evaluations of Catechin Hydrate Polymeric Nanoparticles Used in Brain Targeting for the Treatment of Epilepsy
RETRACTED: Quantification and Evaluations of Catechin Hydrate Polymeric Nanoparticles Used in Brain Targeting for the Treatment of Epilepsy Abstract To formulate novel chitosan (CS)-coated–PLGA–nanoparticles (NPs) using a central composite design approach and use them in order to improve brain bioavailability for catec...
PMC6977340
core_pubmed_pmc
Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, PF‐06648671, on CSF Amyloid‐β Peptides in Randomized Phase I Studies
Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, PF‐06648671, on CSF Amyloid‐β Peptides in Randomized Phase I Studies Abstract Abstract γ‐Secretase modulators (GSMs) represent a promising therapy for Alzheimer's disease by reducing pathogenic amyloid‐β (Aβ) peptide production. Three phase I studi...
PMC12439283
core_pubmed_pmc
Population Pharmacokinetics and Exposure‐Response Relationship of Hemoporfin in Pediatric Patients With Port‐Wine Stain
Population Pharmacokinetics and Exposure‐Response Relationship of Hemoporfin in Pediatric Patients With Port‐Wine Stain Abstract ABSTRACT Hemoporfin, a porphyrin derivative photosensitizer, has been approved for the treatment of port‐wine stain (PWS) in adults. However, its optimal dose for the pediatric population rem...
PMC6858807
core_pubmed_pmc
Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A Galleria mellonella Larval Infection Model
Pharmacodynamics Of Linezolid-Plus-Fosfomycin Against Vancomycin-Susceptible And -Resistant Enterococci In Vitro And In Vivo Of A Galleria mellonella Larval Infection Model Abstract Objectives To explore the in vitro and in vivo antibacterial activity of linezolid/fosfomycin combination against vancomycin-susceptible a...
PMC11291557
core_pubmed_pmc
High prevalence of medication errors in a secondary‐level Lithuanian hospital: A prospective cross‐sectional observational study
High prevalence of medication errors in a secondary‐level Lithuanian hospital: A prospective cross‐sectional observational study Abstract Abstract As the population continues to age, the occurrence of chronic illnesses and comorbidities that often necessitate the use of polypharmacy has been on the rise. Polypharmacy, ...
PMC4603712
core_pubmed_pmc
A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males Abstract Purpose The purpose of this study was to characterize the pharmacokinetics (PKs) and pharmacodynamics (PDs) of an oral inositol-stabilized ...
PMC12351279
core_pubmed_pmc
Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti–B7-H3 × PD-L1 Antibody–Drug Conjugate
Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti–B7-H3 × PD-L1 Antibody–Drug Conjugate Abstract Abstract Purpose: We developed a bifunctional B7-H3 × PD-L1–targeting bispecific antibody–drug conjugate (named DB-1419) conjugated with a novel topoisomerase I inhibitor, P1003 (drug-to-antibody r...
PMC8137473
core_pubmed_pmc
Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals?
Preclinical trial of a MAP4K4 inhibitor to reduce infarct size in the pig: does cardioprotection in human stem cell-derived myocytes predict success in large mammals? Abstract Abstract Reducing infarct size (IS) by interfering with mechanisms for cardiomyocyte death remains an elusive goal. DMX-5804, a selective inhibi...
PMC10733507
core_pubmed_pmc
Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis
Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis Abstract Abstract Background While the majority of patients with atopic dermatitis (AD) achieve disease control with dupilumab treatment, the...
PMC7154008
core_pubmed_pmc
Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study
Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study Abstract Abstract Purpose Trifluridine/tipiracil (FTD/TPI) is approved in Japan, the United States (US), and Europe for metastatic colorectal cancer (mCRC) refractory to ...
PMC10745916
core_pubmed_pmc
Specifics of Pharmacokinetics and Biodistribution of 5-Fluorouracil Polymeric Complex
Specifics of Pharmacokinetics and Biodistribution of 5-Fluorouracil Polymeric Complex Abstract One of the promising and relevant directions in the treatment of oncological diseases is currently the development of a system for the delivery of antitumor drugs based on polyanions. Therefore, the aim of this work was to st...
PMC11937451
core_pubmed_pmc
Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study
Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study Abstract Abstract Background Acute kidney injury (AKI) requiring renal replacement therapy (RRT) is common in intensive care units (ICUs), yet optimal amikacin dosing in this context remains poorly understood. Methods We ...
PMC10859786
core_pubmed_pmc
Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist
Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist Abstract Abstract Buloxibutid (also known as C21) is a potent and selective angiotensin II type 2 receptor (AT2R) agonist, in development for oral treatment of fibrotic lung disease...
PMC6113434
core_pubmed_pmc
Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations
Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations Abstract Abstract Vancomycin is a fundamental antibiotic in the management of severe Gram‐positive infections. Inappropriate vancomycin dosing is associated with therapeutic failure, bacterial resistance and t...
PMC10622746
core_pubmed_pmc
Coadministration of ivermectin and abamectin affects milk pharmacokinetics of the antiparasitic clorsulon in Assaf sheep
Coadministration of ivermectin and abamectin affects milk pharmacokinetics of the antiparasitic clorsulon in Assaf sheep Abstract Abstract In veterinary field, drug exposure during milk production in dairy cattle is considered a major health problem which concerns dairy consumers. The induced expression of the ABC tran...
PMC11662624
core_pubmed_pmc
Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design
Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design Abstract In preclinical studies, GST-HG141, a novel hepatitis B virus (HBV) capsid assembly modulator displayed potent anti...
PMC6364307
core_pubmed_pmc
Current research toward optimizing dosing of first-line antituberculosis treatment
Current research toward optimizing dosing of first-line antituberculosis treatment Abstract ABSTRACT Introduction : Drug concentrations in tuberculosis patients on standard regimens vary widely with clinically important consequences. Areas covered : We review the available literature identifying factors correlated with...
PMC6058259
core_pubmed_pmc
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study Abstract Abstract Essentials Idarucizumab, a monoclonal antibody fragment, binds dabigatran with high affinity and specificity. In this phase 1 trial, healthy Japanese m...
PMC5744174
core_pubmed_pmc
Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid
Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid Abstract Abstract Solithromycin is a fluoroketolide antibiotic under investigation for community‐acquired bacterial pneumonia (CABP). We developed a whole‐body physiologically based pharmacokinetic...
PMC7027461
core_pubmed_pmc
Effect of Food on the Pharmacokinetics of Quizartinib
Effect of Food on the Pharmacokinetics of Quizartinib Abstract Abstract Quizartinib is an oral, highly potent, and selective type II FMS‐like tyrosine kinase 3 inhibitor in development for acute myeloid leukemia. This parallel‐group study evaluated potential food effects on quizartinib absorption in healthy subjects wh...
PMC10544162
core_pubmed_pmc
Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method
Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method Abstract Abstract Escitalopram (SCIT) represents a first-line antidepressant and antianxiety medication. Pharmacokinetic studies of SCIT have demonstrated considerable interindividual variability, emphasizing the need for personalized dos...
PMC10625420
core_pubmed_pmc
Pharmacogenomics in clinical trials: an overview
Pharmacogenomics in clinical trials: an overview Abstract Abstract With the trend towards promoting personalised medicine (PM), the application of pharmacogenetics and pharmacogenomics (PGx) is of growing importance. For the purposes of clinical trials, the inclusion of PGx is an additional tool that should be consider...
PMC12956593
core_pubmed_pmc
Human serum albumin: prediction model and reference values for preterm and term neonates
Human serum albumin: prediction model and reference values for preterm and term neonates Abstract Background Human serum albumin (HSA) concentrations may alter HSA-bound drug distribution. This study aims to describe longitudinal real-world HSA trends, and to develop a prediction model for HSA concentrations using a la...
PMC8929369
core_pubmed_pmc
Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies
Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies Abstract Abstract Pemigatinib is a potent inhibitor of the fibroblast growth factor receptor (FGFR) family of receptors that is approved for the treatment of cholangiocarci...
PMC10668247
core_pubmed_pmc
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors Abstract Background ANV419 is a stable antibody–cytokine fusion protein consisting of interleukin-2 (IL-2) fused to an anti-IL-2 monoclonal antibody that sterically hinders binding of IL-2 to the α subunit ...
PMC6505507
core_pubmed_pmc
Variability Attribution for Automated Model Building
Variability Attribution for Automated Model Building Abstract Abstract We investigated the possible advantages of using linearization to evaluate models of residual unexplained variability (RUV) for automated model building in a similar fashion to the recently developed method “residual modeling.” Residual modeling, al...
PMC8788260
core_pubmed_pmc
Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study
Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study Abstract Abstract Background Current melphalan-based intravitreal regimens for retinoblastoma (RB) vitreous seeds cause retinal toxicity. We assessed the efficacy and toxicity of t...
PMC6979450
core_pubmed_pmc
Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment
Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment Abstract Abstract Introduction The mineralocorticoid receptor (MR) blocker esaxerenone is a new treatment for hypertension in Japan and under development for treatment of diabetic nephropathy. Hepatic im...
PMC10642394
core_pubmed_pmc
From seeds to survival rates: investigating Linum usitatissimum ’s potential against ovarian cancer through network pharmacology
From seeds to survival rates: investigating Linum usitatissimum ’s potential against ovarian cancer through network pharmacology Abstract Ovarian cancer is a malignant tumor that primarily forms in the ovaries. It often goes undetected until it has spread to the pelvis and abdomen, making it more challenging to treat a...
PMC12202192
core_pubmed_pmc
Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies
Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies Abstract Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by dis...
PMC12824591
core_pubmed_pmc
Intrinsic Factors Influencing Simvastatin and Simvastatin Acid Pharmacokinetics: Age‐Related Studies in Thai Adults and Cross‐Population Comparisons
Intrinsic Factors Influencing Simvastatin and Simvastatin Acid Pharmacokinetics: Age‐Related Studies in Thai Adults and Cross‐Population Comparisons Abstract ABSTRACT Intrinsic factors such as age and ethnicity influence statin pharmacokinetics (PK) and may increase the risk of muscle‐related adverse events. This study...
PMC11972936
core_pubmed_pmc
Pharmacokinetics and oral bioavailability of ampicillin and its prodrug bacampicillin in chickens and turkeys
Pharmacokinetics and oral bioavailability of ampicillin and its prodrug bacampicillin in chickens and turkeys Abstract Importance Reports comparing the pharmacokinetics of ampicillin (AMP) and its prodrug bacampicillin (BAC) in poultry are scarce. Objective This study evaluated the pharmacokinetic characteristics of AM...
PMC11641657
core_pubmed_pmc
Innovative Approaches to Fucoxanthin Delivery: Characterization and Bioavailability of Solid Lipid Nanoparticles with Eco-Friendly Ingredients and Enteric Coating
Innovative Approaches to Fucoxanthin Delivery: Characterization and Bioavailability of Solid Lipid Nanoparticles with Eco-Friendly Ingredients and Enteric Coating Abstract Fucoxanthin (FN), a carotenoid derived from brown seaweed and algae, offers significant health benefits. However, its unique structure leads to chal...
PMC5852905
core_pubmed_pmc
Multiresidue Method for Quantification of Sulfonamides and Trimethoprim in Tilapia Fillet by Liquid Chromatography Coupled to Quadrupole Time-of-Flight Mass Spectrometry Using QuEChERS for Sample Preparation
Multiresidue Method for Quantification of Sulfonamides and Trimethoprim in Tilapia Fillet by Liquid Chromatography Coupled to Quadrupole Time-of-Flight Mass Spectrometry Using QuEChERS for Sample Preparation Abstract A multiresidue method for detecting and quantifying sulfonamides (sulfapyridine, sulfamerazine, sulfath...
PMC8592510
core_pubmed_pmc
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase – positive non‐small cell lung cancer
Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase – positive non‐small cell lung cancer Abstract Abstract Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor approved for treatment of ALK ‐positive non‐small cell lung cancer...
PMC7986169
core_pubmed_pmc
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis Abstract Abstract Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We characterized tofacitinib pharmacokinetics in patients with moderate to severe UC, and the ef...
PMC6680204
core_pubmed_pmc
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study Abstract Abstract Aims To compare the pharmacodynamic effects of the highest approved doses of the sodium glucose co‐transporter 2 (SGLT2) inhibitors canagliflozin and dapagliflozin on urinary glu...
PMC9293336
core_pubmed_pmc
Clinical Pharmacokinetics and Safety of a 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel (BF‐200 ALA) in Photodynamic Therapy of Patients Extensively Affected With Actinic Keratosis: Results of 2 Maximal Usage Pharmacokinetic Trials
Clinical Pharmacokinetics and Safety of a 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel (BF‐200 ALA) in Photodynamic Therapy of Patients Extensively Affected With Actinic Keratosis: Results of 2 Maximal Usage Pharmacokinetic Trials Abstract Abstract The nanoemulsion‐based 10% aminolevulinic acid (ALA) hydrochl...
PMC8720984
core_pubmed_pmc
New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia
New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia Abstract Introduction Chagas disease (CD) affects ~7 million people worldwide. Benznidazole (BZN) and nifurtimox ...
PMC8364340
core_pubmed_pmc
Efficacy, Pharmacokinetics, Biodistribution and Excretion of a Novel Acylated Long-Acting Insulin Analogue INS061 in Rats
Efficacy, Pharmacokinetics, Biodistribution and Excretion of a Novel Acylated Long-Acting Insulin Analogue INS061 in Rats Abstract Purpose Long-acting insulin analogues are known to be a major player in the management of glucose levels in type I diabetic patients. However, highly frequent hypo- and hyperglycemic incide...
PMC4899994
core_pubmed_pmc
Altered systemic bioavailability and organ distribution of azathioprine in methotrexate-induced intestinal mucositis in rats
Altered systemic bioavailability and organ distribution of azathioprine in methotrexate-induced intestinal mucositis in rats Abstract Objective: Intestinal mucositis is a significant problem haunting clinicians for decades. One of the major reasons for its occurrence is high-dose chemotherapy. The study is aimed at inv...
PMC12736147
core_pubmed_pmc
Equisetum hyemale L. Extracts: Phytochemistry, Biological Performance, ADMET Profiling, and Toxicity Predictions
Equisetum hyemale L. Extracts: Phytochemistry, Biological Performance, ADMET Profiling, and Toxicity Predictions Abstract Background: Equisetum hyemale L., commonly known as scouring rush or horsetail, is a perennial plant with significant applications in traditional medicine. Methods: The aerial parts of E. hyemale L....
PMC5430868
core_pubmed_pmc
Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients
Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients Abstract The aim of the research was to investigate the pharmacokinetics (PK) of enteric-coated mycophenolate sodium (EC-MPS) by quantification of the active metabolite of myco...
PMC9299913
core_pubmed_pmc
Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial
Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial Abstract Abstract Romiplostim is approved for the treatment of immune thrombocytopenia (ITP). This study aimed to evaluate the pharmacokinetics, safety, and pharmacodynamics of romiplostim ...
PMC9298055
core_pubmed_pmc
Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: A prospective population pharmacokinetic and simulation study
Saliva as a sampling matrix for therapeutic drug monitoring of gentamicin in neonates: A prospective population pharmacokinetic and simulation study Abstract Aims Therapeutic drug monitoring (TDM) of gentamicin in neonates is recommended for safe and effective dosing and is currently performed by plasma sampling, which...
PMC12588668
core_pubmed_pmc
Pharmacokinetic Study of Carboplatin Using Various Overweight-Correcting Dosing Algorithms and Biomarkers in Patients With Varying BMI Categories
Pharmacokinetic Study of Carboplatin Using Various Overweight-Correcting Dosing Algorithms and Biomarkers in Patients With Varying BMI Categories Abstract Supplemental Digital Content is Available in the Text. Background: The Cockcroft–Gault (CG) formula is more likely to overestimate renal function and carboplatin dos...
PMC4387275
core_pubmed_pmc
Pharmacokinetic study of aldoxorubicin in patients with solid tumors
Pharmacokinetic study of aldoxorubicin in patients with solid tumors Abstract Summary Introduction Aldoxorubicin, a prodrug of doxorubicin, binds covalently to serum albumin in the bloodstream and accumulates in tumors. Aldoxorubicin can be administered at doses several-fold higher than doxorubicin can, without associa...
PMC10019440
core_pubmed_pmc
Common Selfcare Indications of Pain Medications in Children
Common Selfcare Indications of Pain Medications in Children Abstract Pain has a multifaceted impact on individuals worldwide, affecting their physical functioning, emotional well-being, and quality of life. Children (age < 18 years) have a high prevalence of conditions associated with pain, such as toothache, headache,...
PMC4211867
core_pubmed_pmc
Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties
Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties Abstract Triterpenoids have been used for medicinal purposes in many Asian countries because of their anti-inflammatory, antioxidant, antiproliferative, anticancer, and anticarcinogenic properties. Bardo...
PMC11729449
core_pubmed_pmc
Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities
Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities Abstract ABSTRACT Monoclonal antibodies (mAbs) are critical components in the therapeutic landscape, but their dosing strategies often evolve post‐approval as new data emerge. This review evaluate...
PMC10644982
core_pubmed_pmc
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF Abstract Abstract In amyotrophic lateral sclerosis, a disease driven by abnormal transactive response DNA-binding protein of 43 kDa aggregation, CSF may contain pathological species of transactive response DNA-binding protein of 43 ...
PMC4559363
core_pubmed_pmc
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study Abstract Background Transthyretin-mediated amyloidosis is an inherited, progressively debilitating disease caused by mutations in the transthyretin gene. This study evaluated the safety, tolerability, pharmacokinetics,...
PMC12172326
core_pubmed_pmc
Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration
Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration Abstract Background Traumatic Brain Injury (TBI) is a major risk factor for neurodegenerative disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD), with neuroinflammation ...
PMC5785874
core_pubmed_pmc
A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption
A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption Abstract Background Oral administration of drugs is convenient and shows good compliance but it can be affected by many factors in the gastrointestinal (GI) system. Consumption of food is one of the ma...
PMC5836949
core_pubmed_pmc
Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial
Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial Abstract Aims Nasal glucagon (NG) is a nasally‐administered glucagon powder, absorbed through the nasal mucosa, design...
PMC4637021
core_pubmed_pmc
A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs
A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs Abstract Abstract Most of the cytotoxic chemotherapeutic agents have poor aqueous solubility. These molecules are associated with poor physicochemical and biopharmaceutical properties, which makes the formu...
PMC11745047
core_pubmed_pmc
Impact of Food Physical Properties on Oral Drug Absorption: A Comprehensive Review
Impact of Food Physical Properties on Oral Drug Absorption: A Comprehensive Review Abstract Abstract Food-Drug Interaction (FDI) refers to the phenomenon where food affects the pharmacokinetic or pharmacodynamic characteristics of a drug, significantly altering the drug’s absorption rate or absorption extent. These Int...
PMC12358303
core_pubmed_pmc
Evaluation of the Drug–Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach
Evaluation of the Drug–Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach Abstract ABSTRACT Despite predicting poor functional outcomes and being a significant patient burden, there are no approved pharmacotherapies to treat symptom...
PMC8984020
core_pubmed_pmc
Pharmacokinetic, Metabolism, and Metabolomic Strategies Provide Deep Insight Into the Underlying Mechanism of Ginkgo biloba Flavonoids in the Treatment of Cardiovascular Disease
Pharmacokinetic, Metabolism, and Metabolomic Strategies Provide Deep Insight Into the Underlying Mechanism of Ginkgo biloba Flavonoids in the Treatment of Cardiovascular Disease Abstract Abstract Ginkgo biloba , known as the “living fossil,” has a long history of being used as botanical drug for treating cardiovascular...
PMC11002851
core_pubmed_pmc
Population pharmacokinetics of gentamicin in acute lymphoblastic leukemia pediatric patients compared to non-oncology patients
Population pharmacokinetics of gentamicin in acute lymphoblastic leukemia pediatric patients compared to non-oncology patients Abstract Understanding the pharmacokinetics of gentamicin is essential in special populations, such as pediatric patients with acute lymphoblastic leukemia (ALL), in light of previous studies i...
PMC10143371
core_pubmed_pmc
Improved Local Anesthesia at Inflamed Tissue Using the Association of Articaine and Copaiba Oil in Avocado Butter Nanostructured Lipid Carriers
Improved Local Anesthesia at Inflamed Tissue Using the Association of Articaine and Copaiba Oil in Avocado Butter Nanostructured Lipid Carriers Abstract Abstract Unsuccessful anesthesia often occurs under an inflammatory tissue environment, making dentistry treatment extremely painful and challenging. Articaine (ATC) i...
PMC9805131
core_pubmed_pmc
An Open‐Label Study to Evaluate the Effect of Eluxadoline on the Single‐Dose Pharmacokinetics of Midazolam in Healthy Participants
An Open‐Label Study to Evaluate the Effect of Eluxadoline on the Single‐Dose Pharmacokinetics of Midazolam in Healthy Participants Abstract Abstract Eluxadoline is a mixed μ‐opioid, κ‐opioid receptor agonist, and δ‐opioid receptor antagonist, approved in the United States for adults with diarrhea‐predominant irritable ...
PMC6482275
core_pubmed_pmc
Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer
Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer Abstract Abstract The aims of this work were to characterize ipatasertib exposure–response (E‐R) relationships in a phase II study and to quantitatively assess benefit‐risk using a clinical utility in...
PMC7877733
core_pubmed_pmc
Occurrence of Morpholine in Central Nervous System Drug Discovery
Occurrence of Morpholine in Central Nervous System Drug Discovery Abstract Developing drugs for the central nervous system (CNS) requires fine chemical modifications, as a strict balance between size and lipophilicity is necessary to improve the permeability through the blood-brain barrier (BBB). In this context, morph...
PMC10550634
core_pubmed_pmc
Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malaria
Pharmacokinetics of single low dose primaquine in Ugandan and Congolese children with falciparum malaria Abstract Summary Background There are no pharmacokinetic data of single low dose primaquine (SLDPQ) as transmission blocking in African children with acute Plasmodium falciparum and glucose-6-phosphate dehydrogenase...
PMC11056520
core_pubmed_pmc
Pharmacokinetics of a continuous intravenous infusion of hydromorphone in healthy dogs
Pharmacokinetics of a continuous intravenous infusion of hydromorphone in healthy dogs Abstract Abstract Introduction Dosing recommendations for hydromorphone intravenous constant rate infusion (IV CRI) are derived from simulations following IV bolus administration. While this extrapolated dose regimen has been describ...
PMC6595298
core_pubmed_pmc
Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation
Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation Abstract Abstract Aims Therapeutic drug monitoring (TDM) can optimize the efficacy of infliximab (IFX) in patients with inflammatory bowel disease (IBD). Because of the delay betwee...
PMC9522294
core_pubmed_pmc
Correlation of Sedline-generated variables and clinical signs with anaesthetic depth in experimental pigs receiving propofol
Correlation of Sedline-generated variables and clinical signs with anaesthetic depth in experimental pigs receiving propofol Abstract Abstract Most of currently available electroencephalographic (EEG)-based tools to assess depth of anaesthesia have not been studied or have been judged unreliable in pigs. Our primary ai...
PMC5242523
core_pubmed_pmc
Polyethylene Glycol Camouflaged Earthworm Hemoglobin
Polyethylene Glycol Camouflaged Earthworm Hemoglobin Abstract Abstract Nearly 21 million components of blood and whole blood and transfused annually in the United States, while on average only 13.6 million units of blood are donated. As the demand for Red Blood Cells (RBCs) continues to increase due to the aging popula...
PMC10810714
core_pubmed_pmc
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV): A Study Combining Modelling and Swiss HIV Cohort Data Abstract Abstract Background Obesity is increasingly prevalent among people with HIV (PWH) and can possibly result in suboptimal antiretroviral drug...